Third dose of AZ’s COVID jab boosts Omicron antibodiesPreliminary data from an ongoing trial of AstraZeneca’s COVID-19 vaccine Vaxzevria has shown that a booster dose stimulates Share XThird dose of AZ’s COVID jab boosts Omicron antibodieshttps://pharmaphorum.com/news/third-dose-of-azs-covid-jab-boosts-omicron-antibodies/
Dream result for Idorsia as FDA clears its insomnia drugSwiss biotech Idorsia has claimed FDA approval for its first product – insomnia treatment Quviviq – setting up Share XDream result for Idorsia as FDA clears its insomnia drughttps://pharmaphorum.com/news/dream-result-for-idorsia-as-fda-clears-its-insomnia-drug/
After a Scottish aye, NICE says no to Lynparza for prostate cancerAstraZeneca’s PARP inhibitor Lynparza should not be made available routinely on the NHS n England and Wales as Share XAfter a Scottish aye, NICE says no to Lynparza for prostate cancerhttps://pharmaphorum.com/news/after-a-scottish-aye-nice-says-no-to-lynparza-for-prostate-cancer/
Applied Therapeutics slumps as FDA seeks more data on lead drugShares in Applied Therapeutics slumped today after it said it would have to delay a US filing for Share XApplied Therapeutics slumps as FDA seeks more data on lead drughttps://pharmaphorum.com/news/applied-therapeutics-slumps-as-fda-seeks-more-data-on-lead-drug/
Biogen, Eisai Alzheimer’s drug lecanemab fast tracked by FDABiogen and Eisai head towards the end of the year with some much-needed good news in their Alzheimer’s Share XBiogen, Eisai Alzheimer’s drug lecanemab fast tracked by FDAhttps://pharmaphorum.com/news/biogen-eisai-alzheimers-drug-lecanemab-fast-tracked-by-fda/
Update: Pfizer pips Merck to first oral COVID antiviral okay in USPfizer’s Paxlovid has become the first oral antiviral for COVID-19 to be authorised for emergency use by the Share XUpdate: Pfizer pips Merck to first oral COVID antiviral okay in UShttps://pharmaphorum.com/news/pfizer-pips-merck-to-first-oral-covid-antiviral-okay-in-us/
NICE backs Aimmune’s peanut allergy drug Palforzia for childrenChildren in England with peanut allergies could be among the first in Europe to get access to Aimmune’s Share XNICE backs Aimmune’s peanut allergy drug Palforzia for childrenhttps://pharmaphorum.com/news/nice-backs-aimmunes-peanut-allergy-drug-palforzia-for-children/
Japan looks set to follow EU in rejecting Alzheimer’s drug AduhelmThe Japanese regulator looks like it could follow the European Commission and reject approval of Biogen and Eisai’s Share XJapan looks set to follow EU in rejecting Alzheimer’s drug Aduhelmhttps://pharmaphorum.com/news/japan-looks-set-to-follow-eu-in-rejecting-alzheimers-drug-aduhelm/
FDA knocks back Takeda’s blockbuster hope TAK-721Japanese drugmaker Takeda has suffered a blow to its late-stage pipeline, after the FDA rejected its marketing application Share XFDA knocks back Takeda’s blockbuster hope TAK-721https://pharmaphorum.com/news/fda-knocks-back-takedas-blockbuster-hope-tak-721/
FDA okays ViiV’s Apretude as first injectable for HIV PrEPGlaxoSmithKline’ majority-owned HIV unit ViiV has scored a key FDA approval, getting approval for its long-acting drug cabotegravir Share XFDA okays ViiV’s Apretude as first injectable for HIV PrEPhttps://pharmaphorum.com/news/fda-okays-viivs-apretude-as-first-injectable-for-hiv-prep/
Relief for AZ, Amgen as FDA okays severe asthma hope tezepelumabThe FDA has approved AstraZeneca and Amgen’s severe asthma hope tezepelumab, exonerating the drugmakers’ decision to press ahead Share XRelief for AZ, Amgen as FDA okays severe asthma hope tezepelumabhttps://pharmaphorum.com/news/relief-for-az-amgen-as-fda-okays-severe-asthma-hope-tezepelumab/
Samantha Roberts to replace Gillian Leng as CEO of NICEProf Gillian Leng’s replacement as chief executive of the National Institute for Health and Care Excellence (NICE) has Share XSamantha Roberts to replace Gillian Leng as CEO of NICEhttps://pharmaphorum.com/news/samantha-roberts-to-replace-gillian-leng-as-ceo-of-nice/
Biogen’s Alzheimer’s drug Aduhelm is rejected by EU advisorsThe EMA’s human medicines committee has said it cannot approve Biogen and Eisai’s Alzheimer’s disease therapy Aduhelm, saying Share XBiogen’s Alzheimer’s drug Aduhelm is rejected by EU advisorshttps://pharmaphorum.com/news/biogens-alzheimers-drug-aduhelm-is-rejected-by-eu-advisors/
As Omicron cases rise, EMA backs early use of Pfizer’s PaxlovidThe EMA’s human medicines committee has said that EU member states can start to offer Pfizer’s oral antiviral Share XAs Omicron cases rise, EMA backs early use of Pfizer’s Paxlovidhttps://pharmaphorum.com/news/as-omicron-cases-rise-ema-backs-early-use-of-pfizers-paxlovid/
NICE gives Keytruda parity with Opdivo for adjuvant melanomaAfter three years of availability via the Cancer Drugs Fund (CDF), MSD’s checkpoint inhibitor Keytruda has now been Share XNICE gives Keytruda parity with Opdivo for adjuvant melanomahttps://pharmaphorum.com/news/after-stint-on-cdf-nice-makes-keytruda-routine-for-adjuvant-melanoma/
EU gives narrower label to Apellis, Sobi’s PNH drugApellis Pharma and partner Sobi have won EU approval for their paroxysmal nocturnal haemoglobinuria (PNH) drug pegcetacoplan in Share XEU gives narrower label to Apellis, Sobi’s PNH drughttps://pharmaphorum.com/news/eu-gives-narrower-label-to-apellis-sobis-pnh-drug/
Wales is first UK country to fund GW’s Epidyolex for tuberous sclerosisPatients in Wales with a rare disease that causes epilepsy will be the first in the UK to Share XWales is first UK country to fund GW’s Epidyolex for tuberous sclerosishttps://pharmaphorum.com/news/wales-is-first-uk-country-to-fund-gws-epidyolex-for-tuberous-sclerosis/
FDA sets April date for verdict on Incyte’s vitiligo drugIncyte could be a few month away from a second FDA approval for its Opzelura cream that would Share XFDA sets April date for verdict on Incyte’s vitiligo drughttps://pharmaphorum.com/news/fda-sets-april-date-for-verdict-on-incytes-vitiligo-drug/
